Although multiple NSCLC studies demonstrate worse OS in patients with KRAS/SMARCA4 co-mutations compared to KRAS-mutated patients, most do not analyze the impact of SMARCA4 class 1 versus class 2 on OS within this co-mutated population [22,24,25]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.